Published in Carcinogenesis on February 24, 2010
Janus kinase 2 is required for the initiation but not maintenance of prolactin-induced mammary cancer. Oncogene (2010) 1.03
Signal transducer and activator of transcription 5 as a key signaling pathway in normal mammary gland developmental biology and breast cancer. Breast Cancer Res (2011) 1.01
Altered AIB1 or AIB1Δ3 expression impacts ERα effects on mammary gland stromal and epithelial content. Mol Endocrinol (2011) 0.92
Comparison of increased aromatase versus ERα in the generation of mammary hyperplasia and cancer. Cancer Res (2011) 0.92
Mouse models of estrogen receptor-positive breast cancer. J Carcinog (2011) 0.91
Scribble modulates the MAPK/Fra1 pathway to disrupt luminal and ductal integrity and suppress tumour formation in the mammary gland. PLoS Genet (2014) 0.86
Comparison of tamoxifen and letrozole response in mammary preneoplasia of ER and aromatase overexpressing mice defines an immune-associated gene signature linked to tamoxifen resistance. Carcinogenesis (2014) 0.83
Oestrogen receptor-alpha regulates non-canonical Hedgehog-signalling in the mammary gland. Dev Biol (2014) 0.82
Assessing estrogen signaling aberrations in breast cancer risk using genetically engineered mouse models. Ann N Y Acad Sci (2011) 0.81
Context-Specific Growth Hormone Signaling through the Transcription Factor STAT5: Implications for the Etiology of Hepatosteatosis and Hepatocellular Carcinoma. Genes Cancer (2011) 0.78
Association of Over-Expressed Estrogen Receptor Alpha with Development of Tamoxifen Resistant Hyperplasia and Adenocarcinomas in Genetically Engineered Mice. Anat Physiol (2012) 0.77
Genetically engineered ERα-positive breast cancer mouse models. Endocr Relat Cancer (2014) 0.77
Roles of ERβ and GPR30 in Proliferative Response of Human Bladder Cancer Cell to Estrogen. Biomed Res Int (2015) 0.76
HDAC6 Deacetylates HMGN2 to Regulate Stat5a Activity and Breast Cancer Growth. Mol Cancer Res (2016) 0.76
Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev (1997) 5.57
Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation. Mol Cell Biol (2004) 4.45
Paracrine signaling through the epithelial estrogen receptor alpha is required for proliferation and morphogenesis in the mammary gland. Proc Natl Acad Sci U S A (2006) 3.32
Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol Metab (2004) 3.10
A novel doxycycline-inducible system for the transgenic analysis of mammary gland biology. FASEB J (2002) 3.05
The role of prolactin in mammary carcinoma. Endocr Rev (2003) 2.95
Cloning and expression of Stat5 and an additional homologue (Stat5b) involved in prolactin signal transduction in mouse mammary tissue. Proc Natl Acad Sci U S A (1995) 2.79
Transcriptional regulation of the cyclin D1 promoter by STAT5: its involvement in cytokine-dependent growth of hematopoietic cells. EMBO J (1999) 2.10
Signal transducer and activator of transcription (Stat) 5 controls the proliferation and differentiation of mammary alveolar epithelium. J Cell Biol (2001) 2.05
The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer. Breast Cancer Res (2004) 2.04
Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol (2004) 2.04
Mammary gland neoplasia in long-term rodent studies. Environ Health Perspect (1996) 1.94
Activation of Stat5a and Stat5b by tyrosine phosphorylation is tightly linked to mammary gland differentiation. Mol Endocrinol (1996) 1.86
Early onset of reproductive function in normal female mice treated with leptin. Science (1997) 1.79
A human breast cell model of preinvasive to invasive transition. Cancer Res (2008) 1.79
Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells. Oncogene (2005) 1.76
Ductal carcinoma in situ: state of the science and roadmap to advance the field. J Clin Oncol (2008) 1.74
Development of mammary luminal progenitor cells is controlled by the transcription factor STAT5A. Genes Dev (2009) 1.69
Stat5a is tyrosine phosphorylated and nuclear localized in a high proportion of human breast cancers. Int J Cancer (2004) 1.60
STAT5 promotes multilineage hematolymphoid development in vivo through effects on early hematopoietic progenitor cells. Blood (2002) 1.55
Deregulated estrogen receptor alpha expression in mammary epithelial cells of transgenic mice results in the development of ductal carcinoma in situ. Cancer Res (2005) 1.46
Dominant negative mutants implicate STAT5 in myeloid cell proliferation and neutrophil differentiation. Blood (1999) 1.42
Pubertal mammary gland development: insights from mouse models. J Mammary Gland Biol Neoplasia (2006) 1.39
Signal transducer and activator of transcription 5a influences mammary epithelial cell survival and tumorigenesis. Cell Growth Differ (1999) 1.38
Overexpression and forced activation of stat5 in mammary gland of transgenic mice promotes cellular proliferation, enhances differentiation, and delays postlactational apoptosis. Mol Cancer Res (2002) 1.38
Loss of Stat5a delays mammary cancer progression in a mouse model. Oncogene (2002) 1.30
Activation of estrogen signaling pathways collaborates with loss of Brca1 to promote development of ERalpha-negative and ERalpha-positive mammary preneoplasia and cancer. Oncogene (2007) 1.24
Basal activation of transcription factor signal transducer and activator of transcription (Stat5) in nonpregnant mouse and human breast epithelium. Mol Endocrinol (2002) 1.22
Distinctive roles of STAT5a and STAT5b in sexual dimorphism of hepatic P450 gene expression. Impact of STAT5a gene disruption. J Biol Chem (1999) 1.20
In vivo identification of novel STAT5 target genes. Nucleic Acids Res (2008) 1.19
Functional rescue of Stat5a-null mammary tissue through the activation of compensating signals including Stat5b. Cell Growth Differ (1998) 1.12
New perspectives into the biological and clinical relevance of oestrogen receptors in the human breast. J Pathol (2007) 1.11
Deregulation of Stat5 expression and activation causes mammary tumors in transgenic mice. Int J Cancer (2004) 1.10
Interactions in the transcriptional regulation exerted by Stat5 and by members of the steroid hormone receptor family. J Steroid Biochem Mol Biol (1999) 1.06
Prolactin signals via Stat5 and Oct-1 to the proximal cyclin D1 promoter. Mol Cell Endocrinol (2005) 1.06
Cross-talk between ERs and signal transducer and activator of transcription 5 is E2 dependent and involves two functionally separate mechanisms. Mol Endocrinol (2001) 1.04
Introduction of estrogen receptor-alpha into the tTA/TAg conditional mouse model precipitates the development of estrogen-responsive mammary adenocarcinoma. Am J Pathol (2003) 1.03
Co-overexpression of Janus kinase 2 and signal transducer and activator of transcription 5a promotes differentiation of mammary cancer cells through reversal of epithelial-mesenchymal transition. Cancer Sci (2008) 1.01
Erythropoietin-induced erythroid differentiation of the human erythroleukemia cell line TF-1 correlates with impaired STAT5 activation. EMBO J (1996) 0.98
Signal transducer and activator of transcription (STAT)-5A and STAT5B differentially regulate human mammary carcinoma cell behavior. Endocrinology (2009) 0.96
The relevance of mouse models to understanding the development and progression of human breast cancer. J Mammary Gland Biol Neoplasia (2008) 0.96
Hypoxia activates the cyclin D1 promoter via the Jak2/STAT5b pathway in breast cancer cells. Exp Mol Med (2005) 0.94
Acceleration of mammary neoplasia in aromatase transgenic mice by 7,12-dimethylbenz[a]anthracene. Cancer Lett (2001) 0.91
ERalpha and STAT5a cross-talk: interaction through C-terminal portions of the proteins decreases STAT5a phosphorylation, nuclear translocation and DNA-binding. FEBS Lett (2004) 0.91
Dominant-negative Stat5 inhibits growth and induces apoptosis in T47D-derived tumors in nude mice. Cancer Sci (2004) 0.90
A simplified method to prepare PCR template DNA for screening of transgenic and knockout mice. Contemp Top Lab Anim Sci (2001) 0.90
Biological features of premalignant disease in the human breast. J Mammary Gland Biol Neoplasia (2000) 0.90
Possible role of Stat5a in rat mammary gland carcinogenesis. Breast Cancer Res Treat (2004) 0.82
Role of the progesterone receptor (PR) in susceptibility of mouse mammary gland to 7,12-dimethylbenz[a]anthracene-induced hormone-independent preneoplastic lesions in vitro. Cancer Lett (2002) 0.82
Premalignant and malignant mammary lesions induced by MMTV and chemical carcinogens. J Mammary Gland Biol Neoplasia (2008) 0.82
Loss of cyclin D1 in concert with deregulated estrogen receptor alpha expression induces DNA damage response activation and interrupts mammary gland morphogenesis. Oncogene (2007) 0.82
Thrombopoietin controls proliferation of embryonic multipotent hematopoietic progenitors. Genes Cells (2009) 0.76
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol (2007) 10.49
The role of prolactin in mammary carcinoma. Endocr Rev (2003) 2.95
Expanding the genetic code for biological studies. Chem Biol (2009) 1.85
Explant-cell culture of primary mammary tumors from MMTV-c-Myc transgenic mice. In Vitro Cell Dev Biol Anim (2004) 1.71
Stat5a is tyrosine phosphorylated and nuclear localized in a high proportion of human breast cancers. Int J Cancer (2004) 1.60
The nuclear receptor coactivator amplified in breast cancer-1 is required for Neu (ErbB2/HER2) activation, signaling, and mammary tumorigenesis in mice. Cancer Res (2008) 1.53
The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells. Mol Endocrinol (2005) 1.52
Impaired meiotic DNA-damage repair and lack of crossing-over during spermatogenesis in BRCA1 full-length isoform deficient mice. Development (2003) 1.49
Deregulated estrogen receptor alpha expression in mammary epithelial cells of transgenic mice results in the development of ductal carcinoma in situ. Cancer Res (2005) 1.46
The PPARγ agonist efatutazone increases the spectrum of well-differentiated mammary cancer subtypes initiated by loss of full-length BRCA1 in association with TP53 haploinsufficiency. Am J Pathol (2013) 1.45
Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions. Endocr Rev (2008) 1.38
Loss of Stat5a delays mammary cancer progression in a mouse model. Oncogene (2002) 1.30
Promotion of mammary cancer development by tamoxifen in a mouse model of Brca1-mutation-related breast cancer. Oncogene (2005) 1.19
Real-time imaging and characterization of human breast tissue by reflectance confocal microscopy. J Biomed Opt (2007) 1.17
Comparison of mouse mammary gland imaging techniques and applications: reflectance confocal microscopy, GFP imaging, and ultrasound. BMC Cancer (2008) 1.10
PTPL1 is a direct transcriptional target of EWS-FLI1 and modulates Ewing's Sarcoma tumorigenesis. Oncogene (2005) 1.03
Introduction of estrogen receptor-alpha into the tTA/TAg conditional mouse model precipitates the development of estrogen-responsive mammary adenocarcinoma. Am J Pathol (2003) 1.03
Overexpression of an N-terminally truncated isoform of the nuclear receptor coactivator amplified in breast cancer 1 leads to altered proliferation of mammary epithelial cells in transgenic mice. Mol Endocrinol (2004) 1.00
BAX regulates follicular endowment in mice. Reproduction (2007) 0.94
Altered AIB1 or AIB1Δ3 expression impacts ERα effects on mammary gland stromal and epithelial content. Mol Endocrinol (2011) 0.92
Comparison of increased aromatase versus ERα in the generation of mammary hyperplasia and cancer. Cancer Res (2011) 0.92
Effect of bilateral oophorectomy on mammary tumor formation in BRCA1 mutant mice. Oncol Rep (2005) 0.91
Effects of ERalpha overexpression on female reproduction in mice. Reprod Toxicol (2006) 0.91
Deregulated estrogen receptor alpha and p53 heterozygosity collaborate in the development of mammary hyperplasia. Cancer Res (2010) 0.90
Reflectance confocal microscopy for characterization of mammary ductal structures and development of neoplasia in genetically engineered mouse models of breast cancer. J Biomed Opt (2005) 0.90
Conditional over-expression of estrogen receptor alpha in a transgenic mouse model. Transgenic Res (2002) 0.90
A fluorescent reporter of the phosphorylation status of the substrate protein STAT3. Angew Chem Int Ed Engl (2011) 0.87
Regulation of progesterone receptor signaling by BRCA1 in mammary cancer. Nucl Recept Signal (2006) 0.86
Methoxychlor induces atresia of antral follicles in ERalpha-overexpressing mice. Toxicol Sci (2006) 0.85
BRCA1 deficient mouse models to study pathogenesis and therapy of triple negative breast cancer. Breast Dis (2010) 0.85
Conditional mouse models demonstrate oncogene-dependent differences in tumor maintenance and recurrence. Breast Cancer Res (2003) 0.84
Functional mimicry of the acetylated C-terminal tail of p53 by a SUMO-1 acetylated domain, SAD. J Cell Physiol (2010) 0.84
Loss of protein phosphatase 2A expression correlates with phosphorylation of DP-1 and reversal of dysplasia through differentiation in a conditional mouse model of cancer progression. Cancer Res (2003) 0.82
Low-volume jet injection for intradermal immunization in rabbits. BMC Biotechnol (2002) 0.82
Trp63 is regulated by STAT5 in mammary tissue and subject to differentiation in cancer. Endocr Relat Cancer (2014) 0.82
BAX is involved in regulating follicular growth, but is dispensable for follicle atresia in adult mouse ovaries. Reproduction (2007) 0.80
Time-lapse imaging of primary preneoplastic mammary epithelial cells derived from genetically engineered mouse models of breast cancer. J Vis Exp (2013) 0.80
The CDK4/6 inhibitor PD0332991 reverses epithelial dysplasia associated with abnormal activation of the cyclin-CDK-Rb pathway. Cancer Prev Res (Phila) (2012) 0.79
Concurrent pregnancy retards mammary involution: effects on apoptosis and proliferation of the mammary epithelium after forced weaning of mice. Biol Reprod (2002) 0.78
Genetically engineered ERα-positive breast cancer mouse models. Endocr Relat Cancer (2014) 0.77
Early parity significantly elevates mammary tumor incidence in MMTV-c-myc transgenic mice. Transgenic Res (2003) 0.77
Chemoprevention of mammary carcinogenesis in a transgenic mouse model by alpha-difluoromethylornithine (DFMO) in the diet is associated with decreased cyclin D1 activity. Oncogene (2003) 0.77